You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Drug Price Trends for ALOSETRON HCL


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ALOSETRON HCL

Best Wholesale Price for ALOSETRON HCL

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
LOTRONEX 0.5MG TAB Sebela Pharmaceuticals, Inc. DBA Sebela Pharmaceuticals, Inc. 54766-0894-03 30 791.73 26.39100 EACH 2024-04-01 - 2029-03-31 Big4
LOTRONEX 0.5MG TAB Sebela Pharmaceuticals, Inc. DBA Sebela Pharmaceuticals, Inc. 54766-0894-03 30 1192.64 39.75467 EACH 2024-04-01 - 2029-03-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Alosetron HCL

Market Overview

Alosetron hydrochloride, commonly known by the brand name Lotronex, is a serotoninergic neuroenteric modulator used primarily for the treatment of irritable bowel syndrome (IBS) in women whose predominant bowel symptom is diarrhea. Here’s a comprehensive analysis of the market and price projections for this drug.

Market Growth and Trends

The global alosetron market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 3.50% from 2021 to 2028. This growth is driven by several key factors:

  • Increasing Cases of IBS: The rising prevalence of irritable bowel syndrome, particularly among women, is a significant driver of market growth[1][3][4].
  • Geriatric Population: The growing count of women in the geriatric population is another factor contributing to the demand for alosetron[1][3].
  • Health Expenditure: Increased health expenditure and the presence of existing alosetron drugs also positively impact the market[1][3].
  • Demand for Oral Tablets: The increasing demand for oral tablets further boosts the market growth[1].

Market Segmentation

The alosetron market is segmented based on several criteria:

  • Dosage Type: The market is segmented into 0.5mg and 1mg oral tablets[1].
  • Applications: The primary applications include chronic irritable bowel syndrome, visceral pain, and gastrointestinal diseases[1].
  • Mode of Purchase: The market is divided into prescription and over-the-counter (OTC) segments[1].
  • Distribution Channel: The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies[1].

Geographical Analysis

Geographically, the market is analyzed across various regions:

  • North America: This region is expected to hold the largest market share due to the high prevalence of IBS, increased availability of alosetron drugs, and supportive health policies. The prevalence of IBS in North America is estimated to be around 10-15%[1][3].
  • Asia-Pacific: This region is anticipated to be the fastest-growing market, driven by the increasing number of clinics and hospitals, rising awareness about IBS symptoms, and a reliable supply of alosetron drugs[1][3].

Competitive Landscape

The competitive landscape of the alosetron market includes several key players, with Lotronex being the prominent brand name. The market also includes approved generic versions of alosetron hydrochloride. Despite the availability of generics, the market remains competitive due to the specific patient population and the need for prescribers to understand the risks and benefits associated with the drug[4].

Price Projections

The prices of alosetron hydrochloride vary based on the dosage and the pharmacy:

  • 0.5mg Oral Tablet: The cost for a 30-tablet supply is approximately $364.94, with a per-unit cost of $12.16[2].
  • 1mg Oral Tablet: The cost for a 30-tablet supply is around $603.10, with a per-unit cost of $20.10[2].

These prices are subject to variations due to stock shortages and other market factors.

Challenges and Restraints

Despite the growth potential, the alosetron market faces several challenges:

  • Stringent Regulatory Protocols: Strict governing protocols and the need for Risk Evaluation and Mitigation Strategies (REMS) can hinder market growth[1][3][4].
  • Lack of Awareness: Limited awareness about the symptoms and prevention of IBS can reduce demand for the drug[1][3].
  • Side Effects: The drug's side effects, such as constipation, can also impact its adoption[5].
  • Supply Chain Issues: Difficulties in the supply chain and logistics can affect the availability of the drug in various distribution channels[1][3].

Opportunities

The market also presents several opportunities for growth:

  • Emerging Markets: Regions with growing healthcare infrastructure and increasing awareness about IBS offer significant opportunities for market expansion[1][3].
  • R&D Activities: Increased government and R&D activities focused on the production of alosetron drugs can enhance market growth[1][3].
  • Healthcare Architecture: Improvements in healthcare architecture and the availability of safe medications are additional factors that can drive the market forward[1][3].

Clinical Efficacy

Clinical trials have demonstrated the efficacy of alosetron hydrochloride in treating IBS:

  • Symptom Relief: Alosetron has been shown to provide significant relief from IBS pain and discomfort, as well as reduce urgency and stool frequency in diarrhea-predominant female patients[5].
  • Comparison Studies: Studies have indicated that alosetron is more effective than other treatments like mebeverine hydrochloride in relieving IBS symptoms[5].

Key Takeaways

  • The global alosetron market is expected to grow at a CAGR of 3.50% from 2021 to 2028.
  • North America holds the largest market share, while Asia-Pacific is the fastest-growing region.
  • The market is driven by increasing cases of IBS, a growing geriatric population, and increased health expenditure.
  • Challenges include stringent regulatory protocols, lack of awareness about IBS, and side effects.
  • Opportunities exist in emerging markets, R&D activities, and improvements in healthcare architecture.
  • Clinical trials have confirmed the efficacy of alosetron in treating IBS symptoms.

FAQs

Q: What is the primary use of alosetron hydrochloride? A: Alosetron hydrochloride is primarily used for the treatment of irritable bowel syndrome (IBS) in women whose predominant bowel symptom is diarrhea.

Q: What are the key drivers of the alosetron market growth? A: The market growth is driven by increasing cases of IBS, a growing geriatric population, increased health expenditure, and the demand for oral tablets.

Q: Which region is expected to hold the largest market share for alosetron? A: North America is expected to hold the largest market share due to the high prevalence of IBS and supportive health policies.

Q: What are the common side effects of alosetron hydrochloride? A: The most commonly reported side effect is constipation, along with other potential gastrointestinal issues.

Q: How does the price of alosetron hydrochloride vary? A: The price varies based on the dosage, with a 30-tablet supply of 0.5mg costing around $364.94 and a 30-tablet supply of 1mg costing around $603.10.

Sources

  1. Data Bridge Market Research: Global Alosetron Market Share, Size, Scope, Industry Trends & Forecast 2028.
  2. Drugs.com: Alosetron Prices, Coupons, Copay Cards & Patient Assistance.
  3. Data Bridge Market Research: Global Alosetron Market Research Report, Future Demand and ...
  4. FDA: Lotronex (alosetron hydrochloride) Information.
  5. JAMA Network: A Randomized Controlled Clinical Trial of the Serotonin Type 3 ...

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.